Article Information
History
- July 13, 2021.
Article Versions
- Version 1 (June 23, 2021 - 10:36).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Phillip A. Swanson II1,*,
- Marcelino Padilla1,
- Wesley Hoyland1,
- Kelly McGlinchey2,
- Paul A. Fields3,
- Sagida Bibi4,
- Saul N. Faust5,
- Adrian B. McDermott1,
- Teresa Lambe6,†,
- Andrew J. Pollard4,†,
- Nicholas M. Durham7,† and
- Elizabeth J. Kelly8,†
- 1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
- 2Discovery, Early Oncology, AstraZeneca, Gaithersburg, MD, USA.
- 3Adaptive Biotechnologies, Seattle, WA, USA.
- 4Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
- 5NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
- 6Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- 7Translational Medicine, Early Oncology, AstraZeneca, Gaithersburg, MD, USA.
- 8Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
- ↵*To whom correspondence should be addressed: Phillip A. Swanson II, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA phil.swanson{at}nih.gov and Elizabeth J. Kelly, Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA beth.kelly{at}astrazeneca.com
↵† These authors contributed equally